Aridis Pharmaceuticals is working on an inhaled neutralizing antibody for COVID-19 dubbed AR-711, which was discovered using samples from patients who had recovered from COVID-19. The drug successfully cleared signs of SARS-CoV-2 virus from infected hamsters at a far lower dose compared with other experimental monoclonal antibodies, according to results published on preprint site bioRxiv.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,